You are here: Home / Infrastructures / Res. Infrastructure
Infrastructure on Production and characterization of Nanomaterials, Biomaterials and systems in Biomedicine (NANBIOSIS)
Hosting Legal Entity
Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN)
Av. Monforte de Lemos, 3-5. Pabellón 11. Planta 0, Madrid, PO: 28029 (Spain)
Jesus Usón Minimally Invasive Surgery Centre (JUMISC)
Carretera N-521, km 41,8, Cáceres, PO: 10071 (Spain)
Av. Monforte de Lemos, 3-5., CIBER-BBN, Madrid, PO: 28029 (Spain)
Type Of RI
Coordinating Country
Current Status:
Operational since 2015
Scientific Description
MissionProvide a complete integrated advance solutions for companies and research institutions under one only entry point through the design and production of biomaterials, nanomaterials and their nanoconjugates, its characterization from a physic-chemical, functional, toxicological and biological (preclinical validation) point of view, focused on biomedical applications such as: IVDs, medical devices, biosensors, regenerative medicine, drug delivery systems, therapeutic agents or MRI contrast agents.VisionNANBIOSIS’ vision is to become a national and international model for companies, institutions and administration as an infrastructure able to perform, with a scientific, technological and regulatory perspective, a complete preclinical validation from the design and synthesis of the product to its in vivo validation.

RI Keywords
Proteins, Monoclonal antibodies, Tissue engineering, Protein production, Purification of biomolecules and nanoparticles, Biosensor technologies, Preclinical studies of pharmaceutical compounds, Biomedical translational research, Nanomedicine, Peptide, Drug delivery, Biomedical imaging, Toxicology, Preclinical in vivo imaging, Protein expression, Biomedical, Drug development, Multimodality preclinical imaging, Nanoconjugates, Protein modifications, Targeting, Immunotoxicology
RI Category
Biological/Biomedical Engineering and Biotechnology/Nanotechnology Research Facilities
Analytical Facilities
Centralised Computing Facilities
Biomedical Imaging Facilities
Micro- and Nanotechnology facilities
Materials Synthesis or Testing Facilities
Scientific Domain
Biological and Medical Sciences
Chemistry and Material Sciences
ESFRI Domain
Health and Food
Validation of Medical Devices

In vivo Validation of medical devices for determined applications in different animal models


- Supply nanomaterials for applications in Nanomedicine: therapy, drug delivery, contras agents (MRI, fluorescence) & theranostic - Pure active pharmaceutical ingredients with controlled nansotructure,

Nanoconjugates & bioconjugates

Supply nanoconjugates for applications in Nanomedicine: therapy, contrast agents (MRI) & theranostic. - Bioconjugation - Nanoconjugation - Micro & nanoencapsulation

In vivo diagnostic

In vivo validation of contrast agents and development of nanoconjugates as contrast agents for MRI and fluorescence: - Nanoparticles - Validation of NPs for glioma - Validation of Contras agents - Nanocojugates for fluorescence - Nanocojugates for MRI

In vitro diagnostic

Development of prototypes and biosensing devices for diagnostic, production of bioreceptor against identified biomarkers an detection of biomarkers for diagnostic, follow-up and prognostic of diseases by NMR spectroscopies in biofluids and tissues.

Customized biomolecules production (Recombinant proteins, Antibodies, haptenes and peptides)

Customized design and production services of biological molecules for Tissue Engineering, Intelligent Devices, Implants, and specially Therapeutic Nanoconjugates and Biosensors by providing for applications such as: − Therapeutic agents - Targeting − Surfaces functionalization: Tissue engineering/scaffolds & biosensors

Nanomedicines Preclinical validation

Preclinical characterization of nanomedicines including physicochemical properties, in vitro and in vivo biological properties (immunology, toxicology an efficacy with appropriated animal models, at either regulatory (cGLP) or non-regulatory conditions: - Complete cascade characterization - Physicochemical characterization - In vitro characterization - In vivo characterization

Biomaterials preclinical characterization

Preclinical validation of biomaterials including surface and mechanical characterization and in vitro and in vivo biological properties with appropriated animal models, at either regulatory (cGLP) or non-regulatory conditions: - Preclinical validation - Surface and mechanical characterization - Adhesion of bacteria: biofilms - Biocompatibility

3D Bioprinting

Design and production of scaffolds for tissue engineering: - Scaffolds - Functionalized scaffolds

Date of last update: 05/06/2019
Printable version